BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Medtronic
US Army
Healthtrust
Harvard Business School
Queensland Health
McKesson
Baxter
Cantor Fitzgerald
Dow

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021759

« Back to Dashboard

NDA 021759 describes ELOXATIN, which is a drug marketed by Sanofi Aventis Us and is included in two NDAs. It is available from three suppliers. There is one patent protecting this drug and four Paragraph IV challenges. Additional details are available on the ELOXATIN profile page.

The generic ingredient in ELOXATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.
Summary for 021759
Tradename:ELOXATIN
Applicant:Sanofi Aventis Us
Ingredient:oxaliplatin
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 021759
Suppliers and Packaging for NDA: 021759
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759 NDA sanofi-aventis U.S. LLC 0024-0590 0024-0590-10 1 VIAL, SINGLE-DOSE in 1 CARTON (0024-0590-10) > 10 mL in 1 VIAL, SINGLE-DOSE
ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759 NDA sanofi-aventis U.S. LLC 0024-0591 0024-0591-20 1 VIAL, SINGLE-DOSE in 1 CARTON (0024-0591-20) > 20 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;IV (INFUSION)Strength50MG/10ML (5MG/ML)
Approval Date:Jan 31, 2005TE:APRLD:Yes
Patent:➤ SubscribePatent Expiration:Feb 9, 2017Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;IV (INFUSION)Strength100MG/20ML (5MG/ML)
Approval Date:Jan 31, 2005TE:APRLD:Yes
Patent:➤ SubscribePatent Expiration:Feb 9, 2017Product Flag?Substance Flag?Delist Request?Y

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;IV (INFUSION)Strength200MG/40ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Nov 17, 2006TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Feb 9, 2017Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021759

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-002 Jan 31, 2005 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-003 Nov 17, 2006 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-001 Jan 31, 2005 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-002 Jan 31, 2005 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-003 Nov 17, 2006 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-001 Jan 31, 2005 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-002 Jan 31, 2005 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-001 Jan 31, 2005 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-001 Jan 31, 2005 ➤ Subscribe ➤ Subscribe
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021759-003 Nov 17, 2006 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Medtronic
Dow
AstraZeneca
UBS
Federal Trade Commission
Deloitte
Chubb
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot